Use of dopamine receptor antagonists in palliative tumor therapy

US6696428B2 · kind B2 · utility

Assignee

• Zentaris GmbH · DE

Inventors

• Bernd Nickel · Mühltal, DE
• Peter Hilgard · Frankfurt, DE
• Thomas Klenner · Ingelheim am Rhein, DE
• Jurgen Engel · Alzenau, DE

Key dates

• Filing date: Aug 2, 2002
• Grant date: Feb 24, 2004
• Expiry date: Aug 2, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The side effect of decrease in body weight caused by the alkylphosphocholines such as miltefosine can be antagonized by certain acetylcholine receptor antagonists such as domperidone and pimozide. The combination of alkylphosphocholine plus the antagonist does not have any effect on the anti-tumor action of the alkylphosphocholine. The combination also caused no new side effects in the animals.